Progen Co., Ltd. (XKON:296160)

Market Cap	94.71B +33.5%
Revenue (ttm)	450.00M +1,700.0%
Net Income	-15.25B
EPS	-3,307.00
Shares Out	15.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,916
Average Volume	11,847
Open	6,390.00
Previous Close	6,310.00
Day's Range	6,000.00 - 6,390.00
52-Week Range	4,640.00 - 9,970.00
Beta	-1.66
RSI	44.13
Earnings Date	n/a

About Progen

Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities. The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments. It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes. The company was founded in 1998 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 296160

Financial Performance

In 2022, Progen's revenue was 450.00 million, a decrease of -67.36% compared to the previous year's 1.38 billion. Losses were -15.25 billion, 135.0% more than in 2021.